Revenue segments as reported by the company.

Diabetes

Oncology

Immunology

Neuroscience

Other

Revenue Segments

Gross Profit, Operating Income, and Net Income as a percentage of Revenue

Gross Margin

Operating Margin

Profit Margin

Margins

An operating expense is an expense a business incurs through its normal business operations. Often abbreviated as OPEX.

Research and development

Marketing, selling and administrative

Acquired in-process research and development

Asset impairment, restructuring and other special charges

Operating Expenses

Year over year growth in Revenue and Operating Expenses.

Revenue Y/Y

OpEx Y/Y

Growth

Shares outstanding refer to a company's stock currently held by all its shareholders, including share blocks held by institutional investors and restricted shares owned by the company's officers and insiders.

Outstanding Shares

Market Cap

Also known as Price/Sales Ratio. Calculated using Average market cap for the quarter / Annualized quarterly revenue.

Revenue Multiple

Eli Lilly

Cialis, ia a competitor to Pfizer's blockbuster Viagra for erectile dysfunction. Cialis maintains an active period of 36 hours.

Cialis

Cymbalta is a serotonin-norepinephrine reuptake inhibitor used predominantly in the treatment of major depressive disorders and generalized anxiety disorder, ranks with Prozac as one of the most financially successful pharmaceuticals in industry history. It is also used in the treatment of fibromyalgia, neuropathy, chronic pain and osteoarthritis.

Cymbalta

Gemzar is a treatment of pancreatic cancer. Gemzar is commonly used in the treatment of pancreatic cancer, usually in coordination with 5-FU chemotherapy and radiology. Gemzar also is routinely used in the treatment of non-small cell lung cancer.

Gemzar

Methadone is an analgesic used frequently in the treatment of heroin, opium and other opioid and narcotic drug addictions.

Methadone

Prozac was one of the first therapies in its class to treat clinical depression by blocking the uptake of serotonin within the human brain. It is prescribed to more than fifty-four million people worldwide.

Prozac

Eli Lilly & Co. engages in the discovery, development, manufacture, and sale of pharmaceutical products. The firm's products consist of diabetes, oncology, immunology, neuroscience, and other products and therapies. The company was founded by Eli Lilly in May 1876 and is headquartered in Indianapolis, IN.

Earnings data Q1 2021

Earnings data Q2 2021

Earnings data Q3 2021

Earnings data Q4 2021

Earnings data Q1 2022

Earnings data Q2 2022

Earnings data Q3 2022

Earnings data Q4 2022

Earnings data Q1 2023

Earnings data Q2 2023

Earnings data Q3 2023

Earnings data Q4 2023

Earnings data Q1 2024

Earnings data Q2 2024

Earnings data Q3 2024

Earnings data Q4 2024

Eli Lilly reports robust Q4 earnings, eyes growth in innovative therapies

Eli Lilly's Q4 2022 earnings call highlighted strong financial performance, pipeline advancements, and strategic initiatives for future growth.
The company's focus on innovation, FDA approvals, and market expansion underscores its commitment to addressing unmet medical needs and driving shareholder value.
Challenges in physician education, obesity treatment development, and market access present areas for strategic focus and investment for sustained growth.
Opportunities in expanding manufacturing capacity, engaging with payers, and capitalizing on consumer interest in obesity treatments position Lilly for continued success in 2023.

Eli Lilly reports robust Q1 growth amidst capacity challenges

Eli Lilly's Q1 2023 performance reflects strong revenue growth and strategic investments in new products and facilities.
While facing challenges in capacity and supply pressure, the company's focus on pipeline advancements and market opportunities positions it for future growth.
Opportunities in international markets, cardiovascular trials, and product promotion present avenues for continued expansion and revenue growth.
Overall, Eli Lilly's financial performance, product strengths, and strategic initiatives demonstrate a resilient and growth-focused approach.

Eli Lilly reports robust Q2 earnings, eyes growth through innovation

Eli Lilly's Q2 earnings call showcased strong financial performance, revenue growth, and advancements in its pipeline, driven by key products and strategic investments.
The company faces challenges in managing increased expenses, supply chain constraints, and regulatory considerations, requiring strategic decision-making and operational agility.
Opportunities lie in expanding market access, leveraging innovative treatments like tirzepatide, and enhancing manufacturing capabilities to drive future growth and competitive advantage.
Overall, Lilly's focus on innovation, market expansion, and addressing health needs positions it well for sustained growth and leadership in the pharmaceutical industry.

Eli Lilly posts robust Q3 results, eyes expansion and commercial growth

Eli Lilly (LLY) showcased strong financial performance and pipeline advancements in Q3 2023.
Challenges include supply restrictions and pricing decisions, but opportunities lie in expansion plans and commercial coverage ramp-up.
Investors advised to focus on guidance range for insights into 2024 expectations.

Eli Lilly posts robust Q4 results, eyes global expansion opportunities

Eli Lilly's strong financial performance in Q4 2023, driven by revenue growth and operational efficiency, sets a solid foundation for future growth.
The company's strategic acquisitions, global expansion plans, and focus on innovation position it well for continued success and market leadership.
Challenges in drug development and manufacturing require careful navigation, but opportunities in new drug trials and market expansion offer avenues for growth.
Overall, Eli Lilly's 2023 was marked by productivity and anticipation of sustained momentum in 2024, reflecting a positive outlook for the company.

Eli Lilly reports robust Q1 growth, eyes pipeline opportunities

Eli Lilly's Q1 performance showcased strong revenue growth, driven by new products and global market expansion.
While facing challenges like low Zepbound volume and manufacturing complexities, Lilly's strengths in innovation and market presence position it well for growth.
Opportunities in pipeline advancements, differentiation in drug portfolios, and potential Alzheimer's treatments signal a promising future for the company.
Overall, Eli Lilly's strategic focus on growth, innovation, and market expansion sets a positive trajectory for continued success.

Eli Lilly reports stellar Q3 results, eyes global expansion opportunities

Eli Lilly's Q3 performance reflects robust revenue growth, driven by new products and strategic investments, positioning the company for continued success.
Key pipeline advancements and revenue guidance raise optimism for future growth, with a focus on global scaling and market expansion initiatives.
Challenges in patient adherence and treatment efficacy are being addressed, while opportunities in market penetration and revenue growth are actively pursued.

Revenue

Cost of revenue

Gross profit

Operating expenses

SG&A

Operating income

EBITDA

Net income

Earnings per share

Total assets

Current assets

Cash & equivalents

Receivables

Inventory

Non-current assets

Net PPE

Intangibles

Total liabilities

Current liabilities

Short term debt

Income tax payable

Non-current liabilities

Long-term debt

Total equity

Stockholders equity

Minority interest

Total liabilities & equity

Total debt

Net debt

Book value per share

Cash from operations

Funds from operations

Change in working capital

Cash from investing

Capital expenditure

Purchase/sale of investments

Purchase/sale of business

Other sources

Cash from financing

Change in stock

Change in debt

Cash dividends paid

Cash from other sources

Net change in cash

Free cash flow

Dividends are one of the best benefits to being a shareholder, but finding a great dividend stock is no easy task. Does Eli Lilly (LLY) have what it takes?

Why Eli Lilly (LLY) is a Top Dividend Stock for Your Portfolio

Is  (LLY) Outperforming Other Medical Stocks This Year?

Is Eli Lilly and (LLY) Stock Outpacing Its Medical Peers This Year?

New indication reflects distinct patient population in the REWIND study – people with type 2 diabetes with multiple cardiovascular risks or established cardiovascular disease New indication reflects distinct patient population in the REWIND study – people with type 2 diabetes with multiple cardiovascular risks or established cardiovascular disease

Trulicity® (dulaglutide) is now indicated as an adjunct to diet, exercise, and standard of care therapy to reduce the risk of non-fatal stroke in adults with type 2 diabetes mellitus who have multiple cardiovascular risk factors or established cardiovascu

Eli Lilly Reports MonarchE Data, And Other News: The Good, Bad And Ugly Of Biopharma

"We developed this antibody and got to proof of concept in six months. Usually, that's more than six years," Eli Lilly CEO Ricks said on CNBC's "Mad Money.

Eli Lilly CEO: Speed and industry cooperation are aiding coronavirus treatment development

Lilly's progress in antibodies treatment is expected to raise investors optimism.

Pharma ETFs to Benefit from Lilly's Coronavirus Antibody Progress

Eli Lilly's (LLY) label expansion application for Olumiant to include atopic dermatitis in Europe patients gets CHMP recommendation for approval in Europe.

Lilly's Olumiant Gets CHMP Nod for Eczema Label Expansion

INDIANAPOLIS, Sept. 20, 2020 /PRNewswire/ -- Eli Lilly and Company (NYSE: LLY) today announced Verzenio® (abemaciclib) in combination with standard adjuvant endocrine therapy (ET) significantly decreased the risk of breast cancer recurrence by 25 percent compared to standard adjuvant ET...

Verzenio® Significantly Reduced the Risk of Cancer Recurrence by 25% for People with HR+, HER2- High Risk Early Breast Cancer

Amgen

Eli Lilly (LLY) is developing several potential neutralizing antibodies to treat COVID-19.

Lilly, Amgen Ink Manufacturing Deal for Coronavirus Antibodies

- Study Met Primary Endpoint of Reduction of Time to Recovery - Additional Analyses Ongoing to Understand Other Clinical Outcome Data - Lilly’s Phase 3 Randomized, Double-Blind, Placebo-Controlled Study of Baricitinib Continues

Baricitinib in Combination with Remdesivir Reduces Time to Recovery in Hospitalized Patients with COVID-19 in NIAID-Sponsored ACTT-2 Trial

Eli Lilly and Company (LLY) Management Presents at Cantor Fitzgerald Healthcare Conference (Transcript)

Lilly (LLY) is developing two coronavirus neutralizing antibody candidates as potential treatment for hospitalized COVID-19 patients. Treatment with one antibody candidate reduces hospitalization rate.

Lilly's Coronavirus Antibody Shows Positive Effect in Phase II

Eli Lilly and Amgen on Thursday announced they will team up to manufacture and distribute Lilly's Covid-19 treatments worldwide, if the treatments get approved, and Eli Lilly stock edged up.
The post Eli Lilly, Amgen Teaming Up On Covid-19 Treatments appeared first on Investor's Business Daily.

Eli Lilly, Amgen Teaming Up On Covid-19 Treatments

Eli Lilly and Co. LLY, +0.58% and Amgen Inc. AMGN, -0.23% said Thursday they will collaborate on COVID-19 antibody treatments as a way to significantly boost global supply capacity.

Eli Lilly and Amgen to collaborate on COVID-19 antibody therapies

Eli Lilly and Co (LLY) Presents at Morgan Stanley Global Healthcare Broker Conference Call - (Transcript)

Eli Lilly And Co (NYSE: LLY) shares were moving higher Wednesday after the large-cap biopharma released positive proof-of-concept data for its LY-CoV555 monoclonal antibody treatment candidate for SARS-CoV-2, the virus that causes COVID-19.

Lilly's Coronavirus Antibody Treatment Found Effective, Safe In Mild-To-Moderate Patients

An experimental COVID-19 treatment hit the mark in an 800-patient clinical trial.

Eli Lilly Reports Success With COVID-19 Neutralizing Antibody Treatment

Eli Lilly stock is climbing slightly higher Wednesday after it became the first company to release antibody drug results. 
The post Eli Lilly Stock Looks Hot on New Antibody Drug Evidence appeared first on InvestorPlace.

Eli Lilly Stock Looks Hot on New Antibody Drug Evidence

Lilly's (LLY) EMPACT-MI study is part of Jardiance's ENPOWER clinical program, which is studying the impact of Jardiance on major clinical cardiovascular and renal outcomes in a spectrum of cardio-renal-metabolic conditions.

Lilly Drug Gets Fast Track to Improve Heart Attack Outcome

Eli Lilly released positive data from a test of a Covid-19 treatment, the second time in three days it's posted positive data on a possible Covid-19 treatment, and Eli Lilly stock rose early.
The post Eli Lilly Posts Positive Data On Covid-19 Treatment In Phase 2 Trials appeared first on Investor's Business Daily.

Eli Lilly Posts Positive Data On Covid-19 Treatment In Phase 2 Trials

Shares of Eli Lilly & Co. LLY, +0.72% gained 2.6% in premarket trading on Tuesday after the drug maker said interim data from a mid-stage clinical trial assessing its experimental antibody treatment reduced the rate of hospitalization as well as viral load in some COVID-19 patients.

Shares of Lilly gain as it discloses promising interim findings for COVID-19 antibody treatment

Eli Lilly announced on Wednesday it had found proof of concept data from an interim analysis of the BLAZE-1 clinical trial that showed a reduced rate of hospitalization for coronavirus patients treated with its neutralizing antibody drug.

Eli Lilly reports a reduced rate of hospitalization for coronavirus patients using its antibody treatment

INDIANAPOLIS, Sept. 16, 2020 /PRNewswire/ -- Eli Lilly and Company (NYSE: LLY) today announced proof of concept data from an interim analysis of the BLAZE-1 clinical trial, showing a reduced rate of hospitalization for patients treated with LY-CoV555.

Lilly announces proof of concept data for neutralizing antibody LY-CoV555 in the COVID-19 outpatient setting

Eli Lilly (LLY) releases positive initial data from a phase III study evaluating Olumiant (baricitinib) in combination with Gilead's remdesivir for hospitalized patients with COVID-19.

Lilly's Olumiant Meets Primary Endpoint in Coronavirus Study

INDIANAPOLIS, Sept. 15, 2020 /PRNewswire/ -- Eli Lilly and Company (NYSE: LLY) has launched an open innovation challenge for individuals and teams across the United States to submit inspiring digital health solutions that can help make life better for people living with atopic dermatitis.

News for Eli Lilly Stock (LLY)